Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Observational Trial
- Enrollment
- 2,300 patients (estimated)
- Sponsors
- Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb
- Trial Type
- Observational
- Last Update
- 4 weeks ago
- SparkCures ID
- 1642
- NCT Identifier
- NCT01688011
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.